Etoricoxib in the treatment of active sacroiliitis in patients with axial spondyloarthritis, including ankylosing spondylitis

Abstract

AIM. To study a trend in active sacroiliitis (ASI) in patients with axial spondyloarthritis (axSpA) during different short-term regimens using etoricoxib (ET) 90 mg. MATERIALS AND METHODS. Forty patients with axSpA, including 30 with ankylosing spondyloarthritis), and ASI (sacroiliac joint (SIJ) osteitis as evidenced by magnetic resonance imaging) were examined and then randomized to 2 groups: 1) 20 patients who took ET 90 mg four days or more a week; 2) 20 patients who received ET 90 mg 3 days or less a week. Osteitis was measured in 4 quadrants of each SIJ (0-3 scores). Its main criterion was considered to be a decrease in total osteitis activity (TOA) 12 week later. RESULTS. In all the patients (n=40), TOA decreased from 6.5 (4; 9) to 2 (0; 5) scores (p

Keywords

• axial spondyloarthritis
• ankylosing spondylitis
• sacroiliitis
• non-steroidal anti-inflammatory drugs
• etoricoxib